Jane Lowe Meisel, MD, presents data from a retrospective study investigating patient characteristics, treatment patterns, and clinical outcomes for tucatinib-based treatment in the real-world setting both overall and following fam-trastuzumab deruxtecan (T-DXd).
HER2-positive breast cancer is characterized by excessive production of the HER2 protein by the breast cancer cells. It is diagnosed by immunological tests and treated by novel targeted therapies.